Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03821857 · ClinicalTrials.gov registry record · Phase 4

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

A Phase 4 study of Alzheimer Disease, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 4
Development phase
614
Enrollment target
2
Study locations

NCT03821857 is a Phase 4 study of Alzheimer Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 614 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03821857, a Phase 4 study of Alzheimer Disease, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 4
Development phase
614 participants
Enrollment target
2
Study locations

Study Summary

The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG 18-F-Flortaucipir

Study Locations (2)

Florida

  • Mayo Clinic - Jacksonville

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 614 participants
Start Date 2019-06-27
Est. Completion 2030-05
Phase Phase 4

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03821857

The ClinicalTrials.gov registry entry for NCT03821857 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (78% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which 18-F-Flortaucipir is the first listed.

NCT03821857 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT03821857 about?

NCT03821857 is a clinical study titled "Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease". The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.

What is the current status of trial NCT03821857?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 614 participants. The study started on 2019-06-27. Estimated completion is 2030-05.

What conditions does trial NCT03821857 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT03821857?

The interventions under investigation include: 18-F-Flortaucipir (DRUG).

Who is sponsoring clinical trial NCT03821857?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03821857 being conducted?

This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.